A detailed history of Verus Capital Partners, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Verus Capital Partners, LLC holds 3,510 shares of VKTX stock, worth $165,777. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,510
Holding current value
$165,777
% of portfolio
0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$49.84 - $70.47 $174,938 - $247,349
3,510 New
3,510 $222,000
Q1 2024

May 07, 2024

BUY
$17.4 - $94.5 $46,979 - $255,150
2,700 New
2,700 $221,000
Q1 2022

Aug 09, 2022

SELL
$3.0 - $4.88 $9,300 - $15,128
-3,100 Closed
0 $0
Q1 2020

May 26, 2020

SELL
$3.45 - $7.95 $690 - $1,590
-200 Reduced 6.06%
3,100 $15,000
Q4 2019

Feb 27, 2020

BUY
$6.38 - $8.73 $21,054 - $28,809
3,300 New
3,300 $26,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.62B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Verus Capital Partners, LLC Portfolio

Follow Verus Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verus Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verus Capital Partners, LLC with notifications on news.